Recombinant porcine sequence factor VIII (rp FVIII ) for acquired haemophilia A: practical clinical experience of its use in seven patients

Abstract excerpt

Introduction A recombinant porcine factor VIII B‐domain‐deleted product (rp FVIII ; OBIZUR , Baxalta Incorporated, Deerfield, IL 60015, USA ) was recently approved for treatment of bleeding episodes in adults with acquired haemophilia A ( AHA ) in the United States. To date, no clinical experience outside the registration study has been reported. Aim To describe early clinical experience using rp FVIII for AHA ....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blood transfusion and management
• Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
• Share to Hemophilia Treatment and Research